Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication

Executive Summary

New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.

You may also be interested in...



New Data Brings Yescarta Closer To Blockbuster Territory

Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.

Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First

As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel